Menstrual irregularity: A possible clinical marker of metabolic dysfunction in women with class III obesity

Gynecological Endocrinology

Volumn 26, Issue 10, 2010, Pages 768-772

  Souza, F A C ^a,b   Dias, R ^a   Fernandes, C E ^a,c   Pimentel, F ^b,d   Dias, D ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

^c FACULDADE DE MEDICINA DO ABC   (Brazil)

^d Unoeste School of Medicine   (Brazil)

Author keywords

Class III obesity; hyperandrogenism; hypothalamic hypophyseal gonadal axis; morbid obesity

Indexed keywords

CHOLESTEROL; FOLLITROPIN; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADULT; AMENORRHEA; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MORBID OBESITY; OBESITY; OLIGOMENORRHEA; OVARY FUNCTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; WAIST HIP RATIO;

ADULT; BODY MASS INDEX; FEMALE; HUMANS; MENSTRUATION DISTURBANCES; METABOLIC DISEASES; OBESITY, MORBID; PROSPECTIVE STUDIES;

EID: 77956530425     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.487603     Document Type: Article

References (13)

1. Mokdad AH, Ford ES, Bowman BA. Prevalência de obesidade, diabetes, saúde obesidade-relacionada e fatores de risco. JAMA 2003;289:76-79.
2. Pasquali RMD. Obesity and androgens: facts and perspectives. Fertil Steril 2006;85:1319-1340.
3. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian. Metabolic Syndrome Study. Diabetes Res Clin Pract 2005.
4. Evans DJ, Hoffman RG, Kalkhoff R, Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 1983;57:304-310.
5. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161:1581-1586.
6. World Health Organization. The use and interpretation of antropometry. Geneva: WHO; 1995.
7. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
9. Oliveira EP, Lima MAD, Souza MLA. Metabolic syndrome, its phenotypes, and insulin resistance by HOMA-IR. Arq Bras Endocrinol Metab 2007;51:1506-1515.
10. Gelonese B, Pareja JC, Lima MMO, Lazarin MACT, Souza ICP, Tambascia EC, Muscelli E. Overcoming metabolic syndrome in severe obesity: adiponectin as a marker of insulin sensitivity and HDL-cholesterol improvements after gastric bypass. Arq Bras Endocrinol Metab 2009;53:227.
11. Gelonese B, Godoy-Matos ACJ, Stabe CFC, Pareja JC, Rosado LEFPL, Queiros EC, Tambascia MA; BRAMS Invetigators. HOMA 1-IR and HOMA 2-IR indexes in indentifying insulin resistance and metabolic syndrome. Arq Bras Endocrinol Metab 2009;53:281.
12. Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest 1989;83:23-29.
13. De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro G, Giorgino R. Inhibitory effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women. Obesity 2006;14:1954-1960.